Rolvedon Market Report 2026

Rolvedon Market Overview

• The Rolvedon market growth in the historic period has been driven by increasing use of chemotherapy regimens, rising incidence of treatment-induced neutropenia • Market expansion is supported by increasing demand for patient-friendly oncology supportive drugs, rising focus on treatment adherence improvement • Growth Driver: Rolvedon A Key Solution For Cancer Patients During Chemotherapy • Market Trend: Biologic Medications Revolutionizing Treatment In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rolvedon Market?

Rolvedon is a medication used to reduce the risk of infection in cancer patients undergoing chemotherapy. It is a long-acting granulocyte colony-stimulating factor (G-CSF) that helps stimulate the production of white blood cells, particularly neutrophils, which are important for fighting infections. The main clinical indications of rolvedon are a primary indication, patient population, and treatment context. Primary indication refers to the main medical condition or disease that a drug, therapy, or medical device is specifically approved and marketed to treat. It is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, catering to various end users such as hospitals and clinics, specialty centers, homecare settings, and research and academic institutions.

What Is The Rolvedon Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for patient-friendly oncology supportive drugs, rising focus on treatment adherence improvement, expansion of outpatient cancer care, growing investments in long-acting biologics, continued development of differentiated g-csf formulations. Major trends in the forecast period include increasing adoption of long-acting g-csf therapies, rising focus on infection risk reduction during chemotherapy, growing preference for reduced dosing frequency treatments, expansion of supportive oncology care protocols, enhanced monitoring of neutrophil recovery.

Global Rolvedon Market Segmentation

1) By Clinical Indication: Primary Indication, Patient Population, Treatment Context 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Hospitals And Clinics, Specialty Centers, Homecare Settings, Research And Academic Institutions

What Is The Driver Of The Rolvedon Market?

The increasing prevalence of cancer is expected to propel the growth of the rolvedon market going forward. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells that can form tumors, invade surrounding tissues, and metastasize to other parts of the body. The increasing prevalence of cancer can be attributed to factors such as aging populations, lifestyle choices, environmental exposures, genetic predisposition, and improved diagnostic techniques. Rolvedon helps cancer patients by stimulating white blood cell production, specifically increasing neutrophil counts to reduce the risk of infection during chemotherapy and support the immune system. For instance, in November 2024, according to PubMed, a US-based federal government research and information organization, reported that by 2050, 35.3 million cancer cases worldwide are expected, a 76.6% increase from the 2022 estimate of 20 million. Therefore, the increasing prevalence of cancer is driving the growth of the rolvedon industry.

Key Players In The Global Rolvedon Market

Major companies operating in the rolvedon market are Hanmi Pharm Co Ltd

Global Rolvedon Market Trends and Insights

Major companies operating in the Rolvedon market are focusing on developing innovative solutions, such as biologic medications, to meet the rising demand for targeted, personalized, and highly effective treatment options with fewer side effects. Biologic medications are advanced therapies derived from living cells, such as proteins or antibodies, that offer greater precision in treating complex conditions compared to traditional small-molecule drugs. For instance, in April 2023, Spectrum Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, achieved a major commercial milestone for Rolvedon (eflapegrastim-xnst), a next-generation biologic therapy used in oncology care. Rolvedon is designed to reduce the incidence of infection, particularly febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. It features a long-acting recombinant G-CSF formulation that enhances neutrophil recovery, improves chemotherapy tolerance, and offers a more predictable therapeutic profile. The assignment of a permanent J-code (J1449) by CMS enables streamlined reimbursement, supports wider clinical adoption, and positions the product to tap into a potential $2 billion market opportunity.

What Are Latest Mergers And Acquisitions In The Rolvedon Market?

In April 2023, Assertio Holdings Inc., a US-based pharmaceutical company, acquired Spectrum Pharmaceuticals, Inc. for an undisclosed amount. With this acquisition, Assertio Holdings, Inc. aims to enhance its oncology portfolio, accelerate revenue growth, and improve market access for its products through strategic integration and operational efficiencies. Spectrum Pharmaceuticals Inc. is a US-based biopharmaceutical company that develops rolvedon for chemotherapy-induced neutropenia.

Regional Insights

North America was the largest region in the rolvedon market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Rolvedon Market?

The rovedon market consists of sales of syringes and injection devices, biologic drugs for neutropenia, diagnostic and monitoring equipment, oncology care kits, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rolvedon Market Report 2026?

The rolvedon market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rolvedon industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.